Summary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA. With the RPDD grant, Kazia Therapeutics may now be eligible to receive a rare pediatric disease priority review voucher if paxalisib gets appr...
Summary Healthcare has been at the forefront amid the COVID-19 pandemic with services ranging from the manufacturing of protective gear to testing units and ventilators. Biotech giant CSL Limited is in the race of developing COVID-19 vacci...
Summary The healthcare sector has been a bright spot in the otherwise dull IPO market in 2020 with seven IPOs already and more in the pipeline. 4DMedical, the Melbourne-based MedTech player, is the latest entrant with ASX listing slated for 7 A...
Summary The periodic return on a stock is the major determinator for an investor to make an investment in it, be it in the form of dividends or capital appreciation. In the last 3 months period, GTG has given a positive return of 100% to the in...
Summary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better tole...
Summary Cann Group Limited continues robust commercial momentum in the June quarter of FY20. During FY20 June quarter, AusCann delivered first products of its controlled-dose capsules. Althea reported strong growth despite COVID-19 disruption ...
Summary Australian Government’s response towards containing the Virus crisis was deemed successful worldwide. Amid the pandemic, healthcare companies supporting the healthcare regime through equipment and software solutions have rec...
Summary Pro Medicus stock has gained over 4,6000%, from once trading at 50 cents per share to ~$24 per share, at present. PME’s Radiology platform Visage 7 has been the catalyst for the success of the Company, which allows medical images ...
Summary GE Healthcare to exclusively distribute Osprey Medical Technology in Russia, Middle East, Central Asia, Europe, Africa, and Turkey. For the fourth quarter of FY20 CLINUVEL has cash receipts approximately A$10.40 million. Clinuvel conti...
Summary Mesoblast disclosed that the Phase 3 clinical trial of Remestemcel-L is anticipated to complete recruitment in September 2020 in the US. At the end of the quarter ended June 2020, Mesoblast had nearly US$129.3 million cash on hand. Dim...
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)
